Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 9.95
SHWDY's Cash to Debt is ranked higher than
82% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SHWDY: 9.95 )
SHWDY' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 9.95

Equity to Asset 0.82
SHWDY's Equity to Asset is ranked higher than
88% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SHWDY: 0.82 )
SHWDY' s 10-Year Equity to Asset Range
Min: 0.62   Max: 0.84
Current: 0.82

0.62
0.84
Interest Coverage 71.57
SHWDY's Interest Coverage is ranked higher than
67% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. SHWDY: 71.57 )
SHWDY' s 10-Year Interest Coverage Range
Min: 16.51   Max: 480.94
Current: 71.57

16.51
480.94
F-Score: 5
Z-Score: 8.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 20.77
SHWDY's Operating margin (%) is ranked higher than
90% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. SHWDY: 20.77 )
SHWDY' s 10-Year Operating margin (%) Range
Min: 3.85   Max: 21.94
Current: 20.77

3.85
21.94
Net-margin (%) 10.88
SHWDY's Net-margin (%) is ranked higher than
82% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. SHWDY: 10.88 )
SHWDY' s 10-Year Net-margin (%) Range
Min: 1.1   Max: 23.63
Current: 10.88

1.1
23.63
ROE (%) 6.56
SHWDY's ROE (%) is ranked higher than
74% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. SHWDY: 6.56 )
SHWDY' s 10-Year ROE (%) Range
Min: 0.78   Max: 17.34
Current: 6.56

0.78
17.34
ROA (%) 5.24
SHWDY's ROA (%) is ranked higher than
79% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. SHWDY: 5.24 )
SHWDY' s 10-Year ROA (%) Range
Min: 0.59   Max: 12.19
Current: 5.24

0.59
12.19
ROC (Joel Greenblatt) (%) 35.47
SHWDY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. SHWDY: 35.47 )
SHWDY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.07   Max: 37.47
Current: 35.47

9.07
37.47
Revenue Growth (3Y)(%) 0.90
SHWDY's Revenue Growth (3Y)(%) is ranked higher than
65% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. SHWDY: 0.90 )
SHWDY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 13.5
Current: 0.9

0
13.5
EBITDA Growth (3Y)(%) 12.60
SHWDY's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SHWDY: 12.60 )
SHWDY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 38.2
Current: 12.6

0
38.2
EPS Growth (3Y)(%) 27.80
SHWDY's EPS Growth (3Y)(%) is ranked higher than
88% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. SHWDY: 27.80 )
SHWDY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 103.5
Current: 27.8

0
103.5
» SHWDY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SHWDY Guru Trades in

SHWDY Guru Trades in

SHWDY Guru Trades in

Q3 2012

SHWDY Guru Trades in Q3 2012

Vanguard Health Care Fund 12,066,234 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SHWDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.60
SHWDY's P/E(ttm) is ranked higher than
79% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.00 vs. SHWDY: 34.60 )
SHWDY' s 10-Year P/E(ttm) Range
Min: 8.8   Max: 147.48
Current: 34.6

8.8
147.48
P/B 2.23
SHWDY's P/B is ranked higher than
80% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. SHWDY: 2.23 )
SHWDY' s 10-Year P/B Range
Min: 0.9   Max: 2.33
Current: 2.23

0.9
2.33
P/S 3.71
SHWDY's P/S is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. SHWDY: 3.71 )
SHWDY' s 10-Year P/S Range
Min: 1.11   Max: 15.5
Current: 3.71

1.11
15.5
PFCF 13.66
SHWDY's PFCF is ranked higher than
96% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 13.66 )
SHWDY' s 10-Year PFCF Range
Min: 6.37   Max: 105.53
Current: 13.66

6.37
105.53
EV-to-EBIT 16.41
SHWDY's EV-to-EBIT is ranked higher than
87% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. SHWDY: 16.41 )
SHWDY' s 10-Year EV-to-EBIT Range
Min: 6.4   Max: 79.7
Current: 16.41

6.4
79.7
PEG 13.31
SHWDY's PEG is ranked higher than
82% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 13.31 )
SHWDY' s 10-Year PEG Range
Min: 0.51   Max: 124.29
Current: 13.31

0.51
124.29
Shiller P/E 27.81
SHWDY's Shiller P/E is ranked higher than
87% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 165.76 vs. SHWDY: 27.81 )
SHWDY' s 10-Year Shiller P/E Range
Min: 10.64   Max: 29.11
Current: 27.81

10.64
29.11
Current Ratio 3.51
SHWDY's Current Ratio is ranked higher than
80% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. SHWDY: 3.51 )
SHWDY' s 10-Year Current Ratio Range
Min: 2.35   Max: 4.24
Current: 3.51

2.35
4.24
Quick Ratio 2.77
SHWDY's Quick Ratio is ranked higher than
80% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SHWDY: 2.77 )
SHWDY' s 10-Year Quick Ratio Range
Min: 1.9   Max: 3.32
Current: 2.77

1.9
3.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.10
SHWDY's Dividend Yield is ranked higher than
72% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. SHWDY: 2.10 )
SHWDY' s 10-Year Dividend Yield Range
Min: 0.6   Max: 4.12
Current: 2.1

0.6
4.12
Dividend growth (3y) 2.60
SHWDY's Dividend growth (3y) is ranked higher than
78% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SHWDY: 2.60 )
SHWDY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37
Current: 2.6

0
37
Yield on cost (5-Year) 2.45
SHWDY's Yield on cost (5-Year) is ranked higher than
72% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. SHWDY: 2.45 )
SHWDY' s 10-Year Yield on cost (5-Year) Range
Min: 0.7   Max: 4.8
Current: 2.45

0.7
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 55.44
SHWDY's Price/Net Current Asset Value is ranked higher than
78% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 55.44 )
SHWDY' s 10-Year Price/Net Current Asset Value Range
Min: 11.94   Max: 287.44
Current: 55.44

11.94
287.44
Price/Tangible Book 2.65
SHWDY's Price/Tangible Book is ranked higher than
82% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. SHWDY: 2.65 )
SHWDY' s 10-Year Price/Tangible Book Range
Min: 1.47   Max: 3.53
Current: 2.65

1.47
3.53
Price/DCF (Projected) 1.30
SHWDY's Price/DCF (Projected) is ranked higher than
92% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. SHWDY: 1.30 )
SHWDY' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 1.07
Current: 1.3

0.62
1.07
Price/Median PS Value 1.66
SHWDY's Price/Median PS Value is ranked higher than
62% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. SHWDY: 1.66 )
SHWDY' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 6.25
Current: 1.66

0.56
6.25
Price/Peter Lynch Fair Value 4.73
SHWDY's Price/Peter Lynch Fair Value is ranked higher than
88% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 4.73 )
SHWDY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.39   Max: 3.82
Current: 4.73

0.39
3.82
Price/Graham Number 2.01
SHWDY's Price/Graham Number is ranked higher than
86% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.05 vs. SHWDY: 2.01 )
SHWDY' s 10-Year Price/Graham Number Range
Min: 0.87   Max: 2.69
Current: 2.01

0.87
2.69
Earnings Yield (Greenblatt) 6.10
SHWDY's Earnings Yield (Greenblatt) is ranked higher than
87% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SHWDY: 6.10 )
SHWDY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 15.5
Current: 6.1

1.3
15.5
Forward Rate of Return (Yacktman) 2.71
SHWDY's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. SHWDY: 2.71 )
SHWDY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 23.1
Current: 2.71

2.5
23.1

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 31
Mar15
Revenue(Mil)
EPS($) 2.30
EPS without NRI($) 2.30

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4507.Japan, SH0.Germany,
Shionogi & Co Ltd.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK